Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 139

    1.

    Minerals in drinking water: impacts on taste and importance to consumer health.

    Whelton AJ, Dietrich AM, Burlingame GA, Schechs M, Duncan SE.

    Water Sci Technol. 2007;55(5):283-91.PMID: 17489421 [PubMed - indexed for MEDLINE]Related articles

    2.

    The evaluation of the diuretic action of parenteral formulations of metolazone.

    Cvetanovic I, Ranade V, Molnar J, Whelton A, Somberg J.

    Am J Ther. 2007 Jan-Feb;14(1):25-9.PMID: 17303972 [PubMed - indexed for MEDLINE]Related articles

    4.

    Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.

    Whelton A, Lefkowith JL, West CR, Verburg KM.

    Kidney Int. 2006 Oct;70(8):1495-502. Epub 2006 Aug 30.PMID: 16941030 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial.

    Alper AB Jr, Tomlin H, Sadhwani U, Whelton A, Puschett J.

    Am J Ther. 2006 May-Jun;13(3):229-35.PMID: 16772765 [PubMed - indexed for MEDLINE]Related articles

    6.

    Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease.

    Whelton A.

    Am J Cardiol. 2006 May 8;97(9A):3-9. Epub 2006 Mar 30. Review.PMID: 16675316 [PubMed - indexed for MEDLINE]Related articles

    7.

    Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery.

    Nussmeier NA, Whelton AA, Brown MT, Joshi GP, Langford RM, Singla NK, Boye ME, Verburg KM.

    Anesthesiology. 2006 Mar;104(3):518-26.PMID: 16508400 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Microporous silicon and biosensor development: structural analysis, electrical characterisation and biocapacity evaluation.

    Lillis B, Jungk C, Iacopino D, Whelton A, Hurley E, Sheehan MM, Splinter A, Quinn A, Redmond G, Lane WA, Mathewson A, Berney H.

    Biosens Bioelectron. 2005 Aug 15;21(2):282-92. Epub 2004 Nov 26.PMID: 16023955 [PubMed - indexed for MEDLINE]Related articles

    9.

    Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.

    Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM.

    N Engl J Med. 2005 Mar 17;352(11):1081-91. Epub 2005 Feb 15.PMID: 15713945 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.

    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG; Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.

    Arch Intern Med. 2005 Jan 24;165(2):161-8. Erratum in: Arch Intern Med. 2005 Mar 14;165(5):551. PMID: 15668361 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The coxib conundrum: lessons from the rise and fall of rofecoxib.

    Whelton A.

    Am J Ther. 2004 Nov-Dec;11(6):417-21. No abstract available. PMID: 15543079 [PubMed - indexed for MEDLINE]Related articles

    13.

    The attribute rating test for sensory analysis.

    Dietrich AM, Whelton AJ, Hoehn RC, Anderson R, Wille M.

    Water Sci Technol. 2004;49(9):61-7.PMID: 15237608 [PubMed - indexed for MEDLINE]Related articles

    14.

    Relationship between intensity, concentration, and temperature for drinking water odorants.

    Whelton AJ, Dietrich AM.

    Water Res. 2004 Mar;38(6):1604-14.PMID: 15016538 [PubMed - indexed for MEDLINE]Related articles

    15.

    Health and aesthetic impacts of copper corrosion on drinking water.

    Dietrich AM, Glindemann D, Pizarro F, Gidi V, Olivares M, Araya M, Camper A, Duncan S, Dwyer S, Whelton AJ, Younos T, Subramanian S, Burlingame GA, Khiari D, Edwards M.

    Water Sci Technol. 2004;49(2):55-62. Review.PMID: 14982164 [PubMed - indexed for MEDLINE]Related articles

    16.

    COX-2-specific inhibitors and the kidney: effect on hypertension and oedema.

    Whelton A.

    J Hypertens Suppl. 2002 Sep;20(6):S31-5. Review.PMID: 12683425 [PubMed - indexed for MEDLINE]Related articles

    17.

    Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

    Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.PMID: 12416791 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.

    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

    Am J Manag Care. 2002 Oct;8(15 Suppl):S401-13.PMID: 12416790 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.

    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

    Am J Manag Care. 2002 Oct;8(15 Suppl):S392-400.PMID: 12416789 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.

    Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators.

    Am J Cardiol. 2002 Nov 1;90(9):959-63.PMID: 12398962 [PubMed - indexed for MEDLINE]Related articles

    21.

    Controversies in COX-2 selective inhibition.

    Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman W, García Rodríguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Willaims GH.

    J Rheumatol. 2002 Jul;29(7):1501-10. Review. No abstract available. PMID: 12136912 [PubMed - indexed for MEDLINE]Related articles

    22.

    Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.

    Osterhaus JT, Burke TA, May C, Wentworth C, Whelton A, Bristol S.

    Clin Ther. 2002 Jun;24(6):969-89.PMID: 12117086 [PubMed - indexed for MEDLINE]Related articles

    23.

    Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.

    White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A.

    Hypertension. 2002 Apr;39(4):929-34.PMID: 11967252 [PubMed - indexed for MEDLINE]Related articlesFree article

    24.

    Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.

    White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB.

    Am J Cardiol. 2002 Feb 15;89(4):425-30.PMID: 11835924 [PubMed - indexed for MEDLINE]Related articles

    25.

    Cardiovascular events and COX-2 inhibitors.

    White WB, Whelton A.

    JAMA. 2001 Dec 12;286(22):2811-2. No abstract available. PMID: 11735749 [PubMed - indexed for MEDLINE]Related articles

    26.

    A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.

    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM.

    Clin Ther. 2001 Sep;23(9):1478-91.PMID: 11589261 [PubMed - indexed for MEDLINE]Related articles

    27.

    Cyclooxygenase-2 inhibition and renal function.

    Whelton A.

    Ann Intern Med. 2001 Jun 5;134(11):1077-8. No abstract available. PMID: 11388825 [PubMed - indexed for MEDLINE]Related articlesFree article

    28.

    Prevention of contrast media-induced renal dysfunction with prostaglandin E1: a randomized, double-blind, placebo-controlled study.

    Sketch MH Jr, Whelton A, Schollmayer E, Koch JA, Bernink PJ, Woltering F, Brinker J; Prostaglandin E1 Study Group.

    Am J Ther. 2001 May-Jun;8(3):155-62.PMID: 11344383 [PubMed - indexed for MEDLINE]Related articles

    29.

    Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics.

    Whelton A.

    Am J Ther. 2000 Mar;7(2):63-74. Review.PMID: 11319575 [PubMed - indexed for MEDLINE]Related articles

    30.

    The position of paracetamol in the world of analgesics.

    Day RO, Graham GG, Whelton A.

    Am J Ther. 2000 Mar;7(2):51-4. No abstract available. PMID: 11319573 [PubMed - indexed for MEDLINE]Related articles

    31.

    Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.

    Whelton A, Maurath CJ, Verburg KM, Geis GS.

    Am J Ther. 2000 May;7(3):159-75. Review. Erratum in: Am J Ther 2000 Sep;7(5):341. PMID: 11317165 [PubMed - indexed for MEDLINE]Related articles

    32.

    COX-1 sparing and COX-2 inhibitory drugs: the renal and hepatic safety and tolerability profiles of celecoxib.

    Whelton A.

    Am J Ther. 2000 May;7(3):151-2. No abstract available. PMID: 11317163 [PubMed - indexed for MEDLINE]Related articles

    33.

    Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.

    Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group.

    Am J Ther. 2001 Mar-Apr;8(2):85-95. Erratum in: Am J Ther 2001 May-Jun;8(3):220. PMID: 11304662 [PubMed - indexed for MEDLINE]Related articles

    34.

    Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors.

    Whelton A.

    Am J Med. 2001 Feb 19;110 Suppl 3A:33S-42S. Review. No abstract available. PMID: 11173048 [PubMed - indexed for MEDLINE]Related articles

    35.

    Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis.

    Schiff MH, Whelton A.

    Semin Arthritis Rheum. 2000 Dec;30(3):196-208. Review.PMID: 11124283 [PubMed - indexed for MEDLINE]Related articles

    36.

    Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

    JAMA. 2000 Sep 13;284(10):1247-55.PMID: 10979111 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    Effects of celecoxib and naproxen on renal function in the elderly.

    Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, Geis GS.

    Arch Intern Med. 2000 May 22;160(10):1465-70.PMID: 10826459 [PubMed - indexed for MEDLINE]Related articlesFree article

    38.

    Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications.

    Whelton A.

    Am J Med. 1999 May 31;106(5B):13S-24S. Review.PMID: 10390124 [PubMed - indexed for MEDLINE]Related articles

    39.

    Acute renal papillary necrosis induced by ibuprofen.

    Atta MG, Whelton A.

    Am J Ther. 1997 Jan;4(1):55-60.PMID: 10423592 [PubMed - indexed for MEDLINE]Related articles

    41.

    Long-Term Treatment with Oral Torsemide and Its Effect on Body Weight and Fluid Balance in Patients with Chronic Renal Insufficiency.

    Whelton A, Smith WB, Wallin JD, Hak LJ, McLean B, Goldstein RJ.

    Am J Ther. 1996 Nov;3(11):743-749.PMID: 11862232 [PubMed - as supplied by publisher]Related articles

    42.

    Atheroembolic Renal Disease.

    Vassalotti JA, Delgado FA, Whelton A.

    Am J Ther. 1996 Jul;3(7):544-549.PMID: 11862288 [PubMed - as supplied by publisher]Related articles

    43.

    Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: A Case Presentation and Review of the Literature.

    Samaniego-Picota MD, Whelton A.

    Am J Ther. 1996 Mar;3(3):248-257.PMID: 11862257 [PubMed - as supplied by publisher]Related articles

    45.

    Renal effects of over-the-counter analgesics.

    Whelton A.

    J Clin Pharmacol. 1995 May;35(5):454-63. Review.PMID: 7657844 [PubMed - indexed for MEDLINE]Related articles

    46.

    Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring.

    White WB, Whelton A, Fox AA, Stimpel M, Kaihlanen PM.

    J Clin Pharmacol. 1995 Mar;35(3):233-8.PMID: 7608310 [PubMed - indexed for MEDLINE]Related articles

    47.

    Recurrent Induction of the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Carotid Endarterectomy.

    Mihyu SS, Scheel PJ Jr, Watson AJ, Perler BA, Whelton A.

    Am J Ther. 1995 Jan;2(1):31-33. No abstract available. PMID: 11850644 [PubMed - as supplied by publisher]Related articles

    48.

    A Study Design for Comparing the Effects of Missing Daily Doses of Antihypertensive Drugs.

    Johnson BF, Whelton A.

    Am J Ther. 1994 Dec;1(4):260-267.PMID: 11835097 [PubMed - as supplied by publisher]Related articles

    49.

    Ambulatory blood pressure monitoring: a new window to decision-making in hypertension.

    Whelton A.

    Clin Cardiol. 1992 Oct;15(5 Suppl 2):II14-7.PMID: 1486726 [PubMed - indexed for MEDLINE]Related articles

    50.

    Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

    Whelton A, Eff J, Magner DJ.

    J Clin Pharmacol. 1992 Sep;32(9):808-15.PMID: 1430300 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...